CARMAT Inactive Instrument
Carmat Share Price Other OTC
Equities
Medical Equipment, Supplies & Distribution
| Sales 2024 * | 20.98M 22.48M 1.77B | Sales 2025 * | 43.62M 46.73M 3.68B | Capitalization | 81.65M 87.48M 6.9B |
|---|---|---|---|---|---|
| Net income 2024 * | -39M -41.78M -3.29B | Net income 2025 * | -30M -32.14M -2.53B | EV / Sales 2024 * | 6.96 x |
| Net Debt 2024 * | 64.27M 68.85M 5.43B | Net Debt 2025 * | 106M 113M 8.92B | EV / Sales 2025 * | 4.29 x |
| P/E ratio 2024 * |
-1.72
x | P/E ratio 2025 * |
-2.4
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Carmat
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | 53 | 31/08/16 |
| Director of Finance/CFO | - | 11/12/18 | |
Marc Grimmé
CTO | Chief Tech/Sci/R&D Officer | - | 24/06/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pierre Bastid
CHM | Chairman | 69 | 04/04/18 |
| Director/Board Member | 61 | 06/05/21 | |
Michael Mack
BRD | Director/Board Member | 77 | 19/04/17 |
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
10/09/2024
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +13.39% | 129B | |
| -9.21% | 11.02B | |
| -16.57% | 7.27B | |
| +41.54% | 5.64B | |
| -31.48% | 4.02B | |
| +8.95% | 3.45B | |
| -19.67% | 2.47B | |
| -16.74% | 1.91B | |
| -23.55% | 1.71B |
